OKYO Pharma Files 6-K Report

Ticker: OKYO · Form: 6-K · Filed: Apr 29, 2026 · CIK: 0001849296

Okyo Pharma Ltd 6-K Filing Summary
FieldDetail
CompanyOkyo Pharma Ltd (OKYO)
Form Type6-K
Filed DateApr 29, 2026
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-issuer

TL;DR

OKYO Pharma filed a 6-K, standard report, no major news.

AI Summary

OKYO Pharma Ltd filed a 6-K report on April 29, 2026. The filing includes standard report documents and exhibits, with no specific financial transactions or operational updates detailed in the provided text. The company's address is listed as 55 Park Lane, London.

Why It Matters

This filing indicates routine reporting activity for OKYO Pharma Ltd, a foreign issuer, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 6-K report with no new material financial or operational information provided.

Key Players & Entities

  • OKYO Pharma Ltd (company) — Filer
  • 0001849296 (company) — CIK number for OKYO Pharma Ltd
  • 2026-04-29 (date) — Filing Date and Period of Report

FAQ

What type of filing is this?

This is a Form 6-K, which is a Report of foreign issuer pursuant to Rules 13a-16 and 15d-16.

When was this filing accepted by the SEC?

The filing was accepted on 2026-04-29 at 07:00:07.

What is the CIK number for OKYO Pharma Ltd?

The CIK number for OKYO Pharma Ltd is 0001849296.

What is the SIC code and industry for OKYO Pharma Ltd?

The SIC code is 2836 for Biological Products, (No Diagnostic Substances), categorized under Life Sciences.

What are the listed addresses for OKYO Pharma Ltd?

Both the Mailing Address and Business Address are listed as 55 PARK LANE LONDON X0 W1K 1NA.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2026 regarding OKYO Pharma Ltd (OKYO).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.